With the recent increase of high-priced drugs, the idea of drug price negotiation in Medicare is receiving more attention as even Part D beneficiaries feel the pinch, said Tricia Neuman, ScD, director of the Kaiser Family Foundation's Program on Medicare Policy and the Project on Medicare's Future.
With the recent increase of high-priced drugs, the idea of drug price negotiation in Medicare is receiving more attention as even Part D beneficiaries feel the pinch, said Tricia Neuman, ScD, director of the Kaiser Family Foundation's Program on Medicare Policy and the Project on Medicare's Future.
Transcript (modified)
Is the push to allow Medicare negotiate drug prices getting more traction now compared with when it was brought up in the past?
I do think it’s getting more traction for a couple of reasons. One, when Sovaldi came onto the market with its $1000-per-pill price tag that really got everybody’s attention. While everybody was thrilled to see a cure, there was also concern about what the cost would be to public payers like Medicaid and Medicare, but also for people who incur high expenditures.
More importantly, and more broadly, drug costs are rising and they are affecting all payers. And this is a big change from what we’ve seen in prior years where—at least in the case of Medicare—drug spending has been growing very slowly, and slower and much lower than what was projected by the Congressional Budget Office (CBO). So something is changing right now, which is giving this issue more traction, and now the presidential candidates are actually talking about this. I think this speaks to the real urgency that the public feels, and that might be the starting point for future discussions and political debate on the topic.
Is Medicare Part D keeping drug spending under control?
Well, it had been since 2006 when the drug benefit was enacted. Medicare drug spending has come in much lower than what the CBO had projected: premiums were relatively flat, people were pretty satisfied with their drug coverage, and it wasn’t getting much attention. That all has changed in the past couple of years with the introduction of Sovaldi and other high-priced drugs. Where suddenly Medicare costs are rising for prescription drugs, premiums are going up, and even people with Part D are feeling the pinch of rising healthcare costs and high prices, which are helped by the drug benefit but not entirely eradicated.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Kathy Oubre on Strategies to Mitigate Challenges When Adopting New Payment Models
February 23rd 2024While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.
Read More
Getting to Know Dr Shauna Downs, Public Health Nutritionist
February 23rd 2024Shauna Downs, PhD, MS, is an associate professor in the Department of Health Behavior, Society, and Policy at the Rutgers School of Public Health. A former figure skater, her research now focuses on interventions to promote healthy and sustainable food choices and exploring how our changing climate, food systems, diet, and nutrition are inextricably linked.
Read More